Takeda Pharmaceutical Co. Ltd. exercised its option to acquire the exclusive license to develop and commercialize CNP-101, Cour Pharmaceutical Development Co. Inc.'s investigational autoimmune disorder drug.
CNP-101, also known as TAK-101, is being developed to treat celiac disease — a disorder in which eating gluten, or protein found in certain grains, elicits an immune response in a patient, causing inflammation and damage to the small intestine.
Under the deal, Northbrook, Ill.-based Cour Pharmaceutical will receive up to $420 million in future payments, along with royalties on sales of any products commercialized from the license.
Japan's Takeda and Cour Pharmaceutical initially agreed to jointly develop the medicine in 2015.
In the 2015 agreement, Takeda was granted an option to acquire the exclusive license following the completion of a phase 2a clinical study. Results from the mid-stage trial — which supported the Japanese drugmaker's decision to exercise its option — showed that patients had well-controlled biopsy proven celiac disease after receiving the experimental treatment.
Takeda will advance the clinical development program of TAK-101 by conducting a dose-ranging in celiac disease patients who are on a gluten-free diet.